Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand- mediated apoptosis

Journal of Neuroimmunology

Volumn 87, Issue 1-2, 1998, Pages 105-113

  Frei, Karl ^a   Ambar, Benjamin ^a   Adachi, Naoto ^a   Yonekawa, Yasuhiro ^a   Fontana, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Fas antigen; Fas ligand; Glioblastoma multiforme

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; GLIOMA; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; TARGET CELL;

ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0032126140     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00065-4     Document Type: Article

References (50)

1. Alderson, L.M., Castleberg, R.L., Harsh, G.R., Louis, D.N., Henson, J.W., 1995. Human gliomas with wild-type p53 express bcl-2. Cancer Res. 55, 999-1001.
2. Alley, M.C., Pacula-Cox, C.M., Hursey, M.L., Rubinstein, L.R., Boyd, M.R., 1991. Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res. 51, 1247-1256.
3. Blancher, A., Roubinet, F., Grancher, A.S., Tremoulet, M., Bonaté, A., Delisle, M.B., Calot, J.P., Pourreau, C., Franks, C., Ducos, J., Rascol, A., Clanet, M., 1993. Local immunotherapy of recurrent glioblastoma multiform by intracerebral perfusion of interleukin-2 and LAK cells. Eur. Cytokine Netw. 4, 331-341.
4. Bögler, O., Huang, H.J.S., Kleihues, P., Cavanee, W.K., 1995. The p53 gene and its role in human brain tumors. Glia 15, 308-327.
5. Färkkilä, M., Jääskeläinen, J., Kallio, M., Blomstedt, G., Raininko, R., Virkkunen, P., Paetau, A., Sarelin, H., Mantyla, M., 1994. Randomised, controlled study of intratumoral recombinant γInterferon treatment in newly diagnosed glioblastoma. Br. J. Cancer 70, 138-141.
6. Fine, H.A., Dear, K.B.G., Loeffler, J.S., Black, P.M., Canellos, G.P., 1993. Metanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597.
7. Fisher, D.E., 1994. Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542.
8. Freeman, S.M., Whartenby, K.A., Freeman, J.L., Abboud, C.N., Marrogi, A.J., 1996. In-situ use of suicide genes for cancer therapy. Semin. Oncol. 23, 31-45.
9. Friesen, C., Herr, I., Krammer, P.H., Debatin, K.-M., 1996. Involvement of the CD95 (APO-1)/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2, 574-577.
10. Gratas, C., Tohma, Y., Van Meir, E.G., Klein, M., Tenan, M., Ishii, N., Tachibana, O., Kleihues, P., Ohgaki, H., 1997. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7, 863-869.
11. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J.-C., Tschopp, J., 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
12. Izumu, I., Mineura, K., Watanabe, K., Kowada, M., 1993. Characterization and chemosensitivity of two cell lines derived from human glioblastomas. J. Neuro-Oncol. 17, 111-121.
13. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., Yagita, H., 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182, 1777-1783.
14. Kerr, J.F.R., Winterford, C.M., Harmon, B.V., 1994. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013-2026.
15. Kroemer, G., 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3, 614-620.
16. Kull, F.C., Cuatrecasas, P., 1983. Estimation of cell number by neutral red content. Applications for proliferative and survival assays. Appl. Biochem. Biotechnol. 8, 97-103.
17. Leithäuser, F., Dhein, J., Mechtersheimer, G., Kroetz, K., Brüderlein, S., Henne, C., Schmidt, A., Debatin, K.M., Krammer, P.H., Möller, P., 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69, 415-429.
18. Lesser, G.J., Grossman, S., 1994. The chemotherapy of high-grade astrocytomas. Semin. Oncol. 21, 220-235.
19. Louis, D.N., Von Deimling, A., Chung, R.Y., Rubio, M.P., Whaley, J.M., Eibl, R.H., Ohgaki, H., Wiestler, O.D., Thor, A.D., Seizinger, B.R., 1993. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol. 52, 31-38.
20. Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E., 1993. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74, 957-967.
21. Mahaley, M.S., Mettlin, C., Natarajan, N., Laws, E.R., Peace, B.B., 1989. National survey of patients of care for brain-tumor patients. J. Neurosurg. 71, 826-836.
22. Mariani, S.M., Matiba, B., Baumler, C., Krammer, P.H., 1995. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25, 2303-2307.
23. Martin, S.J., Green, D.R., 1995. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit. Rev. Oncol. Hematol. 18, 137-153.
24. Matsuyama, T., Hata, R., Tagaya, H., Yamamoto, Y., Nakajima, T., Furuyama, J., Wanaka, A., Sugita, M., 1995. Fas antigen mRNA induction in postischemic murine brain. Brain Res. 657, 342-346.
25. Nagata, S., 1997. Apoptosis by death factor. Cell 88, 355-365.
26. Nagata, S., Golstein, P., 1995. The fas death factor. Science 267, 1449-1455.
27. O'Connell, J., O'Sullivan, G.C., Collins, J.K., Shanahan, F., 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082.
28. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., Nagata, S., 1993. Lethal effect of the anti-Fas antibody in mice. Nature (London) 364, 806-809.
29. Reed, J.C., 1994. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124, 1-6.
30. Reed, J.C., 1995. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North Am. 9, 451-473.
31. Rensing-Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S., Weller, M., Aebischer, P., Krammer, P.H., Fontana, A., 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25, 2253-2258.
32. Rensing-Ehl, A., Malipiero, U.V., Irmler, M., Tschopp, J., Constam, D., Fontana, A., 1996. Neurons induce to express major histocompatibility complex class I antigen are killed via the perform and not the Fas (APO-1/CD95) pathway. Eur. J. Immunol. 26, 2271-2274.
33. Roth, W., Fontana, A., Trepel, M., Reed, J.C., Dichgans, J., Weller, M., 1997. Immunochemotherapy of malignant glioma of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44, 55-63.
34. Saas, P., Walker, P., Hahne, M., Quiquerez, A.-L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., de Tribolet, N., Tschopp, J., Dietrich, P.-Y., 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest. 99, 1173-1178.
35. Stockhammer, G., Brotchi, J., Leblanc, R., Bernstein, M., Schackert, G., Weber, F., Ostertag, C., Mulder, N.H., Mellstedt, H., Seiler, R., Yonekawa, Y., Twerdy, K., Kostron, H., De Witte, O., Lambermont, M., Velu, T., Laneuville, P., Villemure, J.-G., Rutka, J.T., Warnke, P., Laseur, M., Mooij, J.J.A., Boëthius, J., Mariani, L., Meyer, M., Brändli, C., Frei, K., Könü, D., Gianella-Borradori, A., 1997. Gene therapy for glioblastoma multiform: in vivo tumor transduction with the herpes thymidine kinase gene followed by gangciclovir. J. Mol. Med. 75, 300-304.
36. Tachibana, O., Nakazawa, H., Lampe, J., Watanabe, K., Kleihues, P., Ohgaki, H., 1995. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55, 5528-5530.
37. Tachibana, O., Lampe, J., Kleihues, P., Ohgaki, H., 1996. Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiform. Acta Neuropathol. 92, 431-434.
38. Tanaka, M., Suda, T., Takahashi, T., Nagata, S., 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135.
39. Thompson, C.B., 1995. Apoptosis in the pathogenesis of treatment and disease. Science 267, 1456-1462.
40. Trauth, B.C., Klas, C., Peters, A.M.J., Matzku, S., Möller, P., Falk, W., Debatin, K.M., Krammer, P.H., 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Wash. DC) 245, 305-310.
41. von Wild, K.R., Knocke, T.H., 1991. The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma - a phase II study. Neurosurg. Rev. 14, 203-213.
42. Walker, P.R., Saas, P., Dietrich, P.-Y., 1997. Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J. Immunol. 158, 4521-4524.
43. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Nagata, S., 1992a. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (London) 356, 314-317.
44. Watanabe-Fukunaga, R., Brannan, C.I., Itoh, N., Yonehara, S., Copeland, N.G., Jenkins, N.A., Nagata, S., 1992b. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148, 1274-1279.
45. Weller, M., Frei, K., Groscurth, P., Krammer, P.H., Yonekawa, Y., Fontana, A., 1994. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J. Clin. Invest. 94, 954-964.
46. Weller, M., Malipiero, U.V., Aguzzi, A., Reed, J.C., Fontana, A., 1995. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95, 2633-2643.
47. Yang, E., Korsmeyer, S.J., 1996. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 88, 386-401.
48. Yoshida, J., Wakabayashi, T., Mizuno, M., Sugita, K., Yoshida, T., Hori, S., Mori, T., Sato, T., Karashima, A., Kurisu, K., Kiya, K., Uozumi, T., 1992. Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma. J. Neurosurg. 77, 78-83.
49. Yung, W.K.A., 1989. In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg. Rev. 12, 197-203.
50. Yung, W.K., Prados, M., Levin, V.A., Fetell, M.R., Bennett, J., Mahaley, M.S., Salcman, M., Etcubanas, E., 1991. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J. Clin. Oncol. 9, 1945-1949.